key: cord-0956584-vhx6n727
authors: Güemes‐Villahoz, Noemi; Burgos‐Blasco, Barbara; Arribi‐Vilela, Ana; Arriola‐Villalobos, Pedro; Rico‐Luna, Carla M.; Cuiña‐Sardiña, Ricardo; Delgado‐Iribarren, Alberto; García‐Feijoó, Julián
title: Detecting SARS‐CoV‐2 RNA in conjunctival secretions: Is it a valuable diagnostic method of COVID‐19?
date: 2020-07-06
journal: J Med Virol
DOI: 10.1002/jmv.26219
sha: 5a335444e8cf2bb365519d60ce2b9b4c0da7f514
doc_id: 956584
cord_uid: vhx6n727

The main purpose of this study is to evaluate the presence of viral RNA of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) in conjunctival swab specimen of coronavirus disease 2019 (COVID‐19) patients with and without conjunctivitis to establish the diagnostic value of reverse transcription‐polymerase chain reaction (RT‐PCR) in each case and to describe its clinical characteristics. A cross‐sectional study was conducted at the Hospital Clinico San Carlos of Madrid, Spain. Thirty‐six subjects from the COVID admission unit with laboratory‐confirmed SARS‐CoV‐2 infection were included. Conjunctival swabs were collected from 18 patients with conjunctivitis and 18 patients without conjunctivitis and RT‐PCR was performed. Conjunctival swab was collected from both eyes of 36 patients (72 eyes), detecting SARS‐CoV‐2 RNA in conjunctival swab of two patients (5.5%). Among the 18 patients with conjunctivitis, only one of them (5.5%) showed positive results. Likewise, SARS‐CoV‐2 RNA was detected in one patient without conjunctivitis (5.5%). The mean age of the 36 patients was 67.9 years (range, 28‐92 years) and the male‐to‐female ratio was 0.44 (16:20). The mean days since the onset of COVID‐19 symptoms until conjunctivitis manifestation was 8 (range, 1‐24 days). The mean duration of the conjunctivitis was 3 days (range, 1‐7 days). SARS‐CoV‐2 RNA may be detected in conjunctival swabs of both patients with and without conjunctivitis. This study revealed the same rate of positive results amongst the group with and without conjunctivitis, suggesting that detecting SARS‐CoV‐2 in ocular fluids is not conditioned on the presence of conjunctivitis. The presence of SARS‐CoV‐2 RNA in ocular samples highlights the role of the eye as a possible route of transmission of the disease.

The main purpose of this study is to assess the presence of viral RNA of SARS-CoV-2 in conjunctival swab specimens of COVID-19 patients with and without conjunctivitis to establish the diagnostic value of reverse transcription-polymerase chain reaction (RT-PCR) in each case. Our secondary objective is to describe the clinical characteristics of conjunctivitis in a group of patients with laboratoryconfirmed SARS-CoV-2 infection. The vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Hospitalized patients for COVID-19 with and without conjunctivitis were consecutively recruited. The inclusion criteria were: over 18 years of age, positive RT-PCR test from nasopharyngeal swab for SARS-CoV-2, hospitalized due to COVID-19, and ability to give verbal consent. Critically ill patients and those unwilling or unable to give verbal consent were excluded.

For this study, a notification system was implemented for all health care personnel working at the COVID unit and evaluating the patients daily. Through this system, the ophthalmology department was notified daily of any new case of conjunctivitis amongst COVID-19 hospitalized patients. Cases reported as possible conjunctivitis were evaluated by two ophthalmologists during the first 24 hours after notification, and a conjunctival swab was collected from confirmed cases that also had positive RT-PCR from a nasopharyngeal swab. Consecutively, the sample from the patient's admitted to the following room number without conjunctivitis and confirmed SARS-CoV-2 infection was collected applying the same procedure. Both the examination and the sampling were carried out by the same physicians (N.G. and B.B.), following appropriate infection control and prevention measures. Patients with conjunctivitis were followed-up until resolution.

The conjunctival swab was collected from both eyes in every patient with a sterile synthetic fiber swab (Flexible Minitip Size Nylon Flocked Swab) into the lower fornix without topical anesthesia.

We used the same swab to obtain a specimen from both eyes, first collecting the sample from the healthy eye in case of unilateral conjunctivitis. Caution was taken to avoid the possibility of sample contamination. The swab was immersed into a viral transport medium (Universal Transport Media; Copan, Italy), and stored at 4°C before being tested for SARS-CoV-2. RT-PCR assays were processed at the clinical microbiology laboratory of HCSC with quantitative GeneXpert Xpert Xpress SARS-CoV-2 (Cepheid). The cycle threshold (C t ) was measured.

The patient's age, sex, chest X-ray, laboratory test results (C-reactive protein), and days since onset of COVID-19 symptoms were obtained through the review of the patients' medical records. Also, clinical disease was classified as mild, moderate, severe, or critical based on CURB-65 score, physical examination, respiratory assessment (respiratory rate, dyspnea, blood oxygen saturation, and ventilation system requirements), or organ failure. As for the ophthalmological examination, the following variables were recorded: laterality, eye redness and discharge, duration of conjunctivitis, and treatment.

The main outcome measure is the overall proportion of positive RT-PCR test from conjunctival swab amongst COVID-19 in patients with and without conjunctivitis.

Regarding statistics, the overall prevalence results from the patients who tested positive for SARS-CoV-2 in the RT-PCR test from the conjunctival swab and it will be presented as a percentage of the total number of patients. The prevalence of positive RT-PCR among patients with conjunctivitis will be presented as a percentage of the total number of patients with conjunctivitis. The prevalence of positive RT-PCR among patients without conjunctivitis will also be presented as a percentage of the total number of patients without conjunctivitis. The distribution of sex, acute pneumonia, clinical severity, and the ophthalmological examination's findings will be presented as percentages. Likewise, the distribution of the quantitative covariates (age, C-reactive protein, days since onset of COVID-19 symptoms, and duration conjunctivitis) will be depicted through the median, first and third quartiles. Table 1) .

The main clinical characteristics found on the patients with conjunctivitis are shown in Table 2 The one patient with conjunctivitis and positive SARS-CoV-2 conjunctival swab results was a 92-year-old male classified as a severe case, but without pneumonia on chest X-ray. He presented conjunctivitis symptoms 5 days after onset of COVID-19 manifestations, which were fatigue, dizziness, and confusion. The C t value measured in this patient was 25, which means an elevated viral load.

In general, C t levels are inversely proportional to the viral load. Table 3 The natural history of the conjunctivitis in patients with COVID-19 seems to be a self-limiting conjunctivitis that improves in a few days without specific treatment. We did not find in our sample short-term complications associated to it, such as the presence of corneal infiltrates, membranes, or pseudomembranes. These characteristics differ to conjunctivitis of other etiologies, which has not been previously described.

Conjunctivitis has been associated with a more severe form of showed positive results to better understand the viral dynamics and quantify the C t throughout the disease process.

In conclusion, SARS-CoV-2 RNA may be detected in tears and conjunctival swabs of both patients with and without conjunctivitis. Our study revealed the same rate with positive results amongst the group with and without conjunctivitis, suggesting that detecting SARS-CoV-2 in ocular fluids may not conditioned by the presence of conjunctivitis.

Further studies are required to assess the risk of SARS-CoV-2 transmission through ocular secretions and the diagnostic value of RT-PCR in patients with and without conjunctivitis.

World Health Organization. Pneumonia of unknown cause-China

Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease

Genomic characterization of a novel SARS-CoV-2

Conjunctivitis can be the only presenting sign and symptom of COVID-19

Clinical characteristics of coronavirus disease 2019 in China

Conjunctivitis and COVID-19: a meta-analysis

Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graefe's Arch Clin Exp Ophthalmol

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients

SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection

Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a crosssectional study

Detecting SARS-CoV-2 RNA in conjunctival secretions: Is it a valuable diagnostic method of COVID-19?

The authors declare that there are no conflict of interests.

http://orcid.org/0000-0003-2178-6164